Embed Size (px)
Citation preview
FIMOis a data driven solution
to improve the quality of lifefor people suffering from fatigue
2
3
AFFECTED
1.1M(in GERMANY)
CHARAKTERISTICS
Extreme exhaustionTiredness
Cognitive disorders
DISORDERS
CancerMultiple SclerosisVirus infections
3
EXPLANATION OF A PATIENT
Source: German Multiple Sclerosisself-aid facebook group:„In 2019 everyone understands the following explanation. Fatigue is like charging your smartphone in the evening and in the morning the battery is still at 40%. Then you write 2 Whatsapp messages and the battery is in the red area. My body behaves the same way with fatigue.”
4
Physical Activity
Cognitive Activity
Noise
Temperature
Light
Stress
FATIGUE HAS MANY INFLUENCING FACTORS
5
VITAL PARAMETERS ENVIRONMENT
Temperature
Noise
Air pressure
Light
Weather
Passive Data measurement Active Data measurement
Symbol Digit Modalities Test WEIMuS Test
Pulse
HRV
Sleep
Physical activity
Stress
6
PROTOTYPE SOLUTION
Measurements ofrelevant data within
everyday life throughan app and a device
Big data analysis & machine learning
algorithms
7
SOLUTION - APPROACH
b
e
n
e
f
i
t
Startup phase
early stage mid stage late stage
DashboardPassive data collectionCharts and data export
All of the early stage:+ significance tests+ individual warnings
All of the mid stage:+ possible warningsbased on cross-sectional data
8
SOLUTION – CLIENT INTERACTION
Better understanding andpredictability of symptoms
Higher trust fromdoctors and family
Improved therapies Earlier diagnosis
VISION
9
SOLUTION – BENEFITS
~ 1 MPatients
~ 50 MPatients
> 5 Bn €R&D for new drugs
> 20 Bn €for therapies
and drugs
10
MARKET SIZE
Multiple Sclerosis 216‘ (2.500‘)
Cancer 429‘ (17.000‘)
CFS/ME 240‘ (17.000‘)
Parkinson 200‘ (6.100‘)
Stroke tbd tbd tbd
…
„healthy people“: air traffic controllers,
truck drivers, …tbd
Customer Group
Size in thousands(worldwide)
Relevance Access
1
2
311
TARGET USER GROUPS
Health insurance providers
benefit from decreasing costs, for example because fewer hospital stays are necessary and better treatments
are possible
B2B2C
Pharmaceutical companies
can measure and prove the efficacy of drugs & therapies
B2B
BUSINESS MODELL
12
All relevant datais measured
Medical contextis provided
Data analytics&
machine learning
Clear focuson fatigue
14
USP
15
DISEASES
Fatigue
Migraine
Narcolepsy
MOBILITY
Pilots / Air trafficcontrollers
Truck or Uber drivers
OTHER
Fitness: High performance sports
Security: Industrial workers
VISION
AlexanderKrawinkel
CEO
TEAM
DominikStiegeler
CTO
BenedictHöger
Head of IT
Jana Mäcken
Biostatistics
KiraHülsdünker
Health
MauriceKlaffehn
IT
M. Sc. Geography& Economics
B. Sc. Computer Science
B. Sc. ElectronicalEngineering
B. Sc. Computer Science
Ph.D. SocialPsychology
Medical Student
16
17
Prof. Dr. Andreas Mayr
Head of WG StatisticalMethods in Epidemiology
Prof. Dr. med.Michael Linnebank
Medical Director, Neurologyclinic Hagen-Ambrock
Prof. Dr. med.Stephanie Stock
Head of Institute for Health Economics and
Clinical Epidemiology
Prof. Dr. med.Andrew Chan
Clinical DirectorUniversitätsspital Bern
MENTORS & PARTNERS
1
2
3
4
2019• Clinical Trial• Exist scholarship
2020• Validation study• Seed funding
2021
2022• Series A• Market entry
• Medical device certification• Ready2Market product€ $
18
TIMELINE
19
Seed funding in 2020: $ 500k – 1M
Experts from pharmaceutical groups and health insurance providers
WE ARE LOOKING FOR…
Contact: [email protected] or visit www.fimo.io
